Publication

Video

Supplements and Featured Publications
Therapeutic Changes in HER2+ Breast Cancer
Volume 1
Issue 1

Novel Treatments in HER2-Positive Breast Cancer

OncLive interviewed experts on novel treatments in HER2-positive breast cancer. 

OncLive interviewed experts on novel treatments in HER2-positive breast cancer.

Supported by an unrestricted educational grant by Daiichi Sankyo

Articles in this issue
Novel Treatments in HER2-Positive Breast Cancer
Novel Treatments in HER2-Positive Breast Cancer
Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer
Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer
Dr. Hurvitz on Treatment Options in Early-Stage HER2+ Breast Cancer
Dr. Hurvitz on Treatment Options in Early-Stage HER2+ Breast Cancer
Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer
Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer
Dr. Krill-Jackson on the Potential Utility of Trastuzumab Deruxtecan in Metastatic Breast Cancer
Dr. Hurvitz on Additional Research Needed With Trastuzumab Deruxtecan in HER2+ Breast Cancer
Dr. Hurvitz on Additional Research Needed With Trastuzumab Deruxtecan in HER2+ Breast Cancer
Related Videos
BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation To Address The Evolved Landscape Of EGFR Mutant NSCLC
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Daniel M. Halperin, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
BTK Inhibitors in CLL : Second Generation Drugs and Beyond
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Related Content
Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

Benjamin Levy, MD, clinical director, medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Sibley Memorial Hospital; associate professor, oncology, Johns Hopkins University School of Medicine
May 30th 2024

Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC

Ivonescimab Improves PFS in PD-L1+ NSCLC : © stock.adobe.com
May 31st 2024

First-Line Ivonescimab Improves PFS vs Pembrolizumab in PD-L1+ NSCLC in China

Oncology Unplugged
May 30th 2024

Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University
May 31st 2024

Asciminib Bests Standard-of-Care TKIs in Ph+ CML

Benjamin J. Solomon, MBBS, PhD
May 31st 2024

Lorlatinib Yields Longest Reported PFS in Advanced NSCLC